Anti-EGF-Receptor (Epidermal Growth Factor Recptor, erbB, EGFR), Extracellular Domain, clone 0.N.266

EGFR is type I receptor tyrosine kinase with sequence homology to erbB-1, -2, -3 -4 or HER-1, -2, -3 -4. It binds to Epidermal Growth Factor (EGF), Transforming Growth Factor-a (TGFa), Heparin-binding EGF (HB-EGF), amphiregulin,, betacellulin and epiregulin. EGFR is overexpressed in tumors of breast, brain, bladder, lung, gastric, head and neck, esophagus, cervix, vulva, ovary, and endometrium. It is predominantly present in squamous cell carcinomas. Applications: Suitable for use in Immunoprecipitation, Blocking EGT/TGFa-Induced Activation of EGFR and Inhibits binding of E3375-03. Other applications have not been tested. Recommended Dilutions: Blocking EGF/TGFa-induced activation of EGFR: 0.5ug/ml, cells induced by 30ng/ml EGF., Immunoprecipitation (Native only): 2ug/mg protein lysate. Use Protein G. , Optimal dilutions to be determined by the researcher. Positive Control: A431 cells, Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.